We are pleased to announce the release of the EORTC 2023 Annual Report

The EORTC Annual Report represents a valuable opportunity to celebrate our recent milestones and reaffirm our mission and goals. Whether you have been familiar with EORTC for many years or have just joined our network, you will find insightful information that provides a comprehensive overview of our work at EORTC.

This year’s edition includes a new chapter dedicated to the EORTC Scientific Strategy, outlining the priorities for our research programmes aimed at enhancing survival and quality of life for cancer patients. This strategic focus is crucial as we navigate the evolving landscape of clinical cancer research. For the first time, we also highlight the contributions of young and early career investigators, showcasing the next generation of researchers committed to advancing cancer treatment and care. Additionally, we feature dedicated chapters on the two EORTC councils: the newly established Older Adults Council (OAC) and the Radiation Oncology Scientific Council (ROSC).

EORTC’s continuous progress is made possible by its extensive network, which in 2023 reached over 3,800 members from diverse disciplines across 58 countries. Our commitment to methodological, scientific, and regulatory advancements in oncology remains strong, as does our dedication to education in clinical research-related science. With 22,700 patients in follow-up and more than 215,000 patients in our databases, EORTC remains the leading independent non-profit clinical cancer research organisation in Europe.

We extend our sincere gratitude to all the people who support, collaborate, and believe in the mission of EORTC to improve the survival and quality of life for cancer patients worldwide. Explore the full EORTC Annual Report 2023 to learn more.

Back to news list

Related News

  • Meet the new EORTC Board

  • Dr Denis Lacombe, EORTC CEO, appointed stakeholder co-chair of ACT EU advisory group

  • Clinical Trials Day 2024: a Q&A on pragmatic clinical trials

  • EORTC/EMA workshop suggests an international way forward for treatment optimisation studies

  • EORTC’s Participation at the ESTRO Congress 2024

  • EORTC: Advancing research and treatment for rare cancers

  • EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration

  • Appointment of Malte Peters as EORTC Strategic Alliance Officer

  • Unique series of workshops in partnership with the European Medicines Agency (EMA)

  • EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)